Maryland’s opioid overdose rate remains among the highest in the nation, with fentanyl driving more than 90% of fatal overdoses in the state according to the Maryland Department of Health’s 2023 data. If you’re looking into a sublocade injection in Maryland, you’re considering one of the most effective medication-assisted treatments available, and this guide walks you through exactly what to expect, from the first appointment through the first 90 days.
What Sublocade Is and How It Works
Sublocade is a once-monthly, extended-release buprenorphine injection administered subcutaneously by a licensed provider in office. The FDA approved it in 2017 specifically for moderate-to-severe opioid use disorder in adults. Unlike a pill or film you take every morning, Sublocade forms a small depot under the skin that releases buprenorphine steadily over the course of the month, maintaining consistent blood-plasma levels without the peaks and valleys that come with daily dosing.
That consistency is the clinical point. When buprenorphine levels fluctuate throughout the day, cravings tend to fluctuate with them. A flat, sustained level removes that cycle entirely, which means no daily decision to take your medication and no window mid-afternoon where the drug level drops and the pull toward opioids intensifies.
How Sublocade Differs from Suboxone and Subutex
Suboxone and Subutex are sublingual formulations: films or tablets that dissolve under the tongue and absorb through the mucous membrane. They work, but they require daily adherence and produce modest peaks and troughs in plasma concentration throughout the day.
Sublocade delivers buprenorphine differently. The subcutaneous injection bypasses daily dosing entirely, which means no morning ritual, no film to carry, and no dose to miss. The pivotal Phase 3 randomized controlled trial by Indivior, published in JAMA Psychiatry by Haight et al. in 2019 (n=504), found that 59.8% of patients receiving Sublocade had no confirmed illicit opioid use during the primary efficacy period of weeks 5 through 24, compared to 16% in the placebo group. The mechanism behind that gap is straightforward: consistent drug levels reduce the reinforcing contrast between baseline and intoxication that drives compulsive use.
Many patients transition to Sublocade after stabilizing on daily Suboxone. If you want to understand how the two formulations compare day-to-day, that context helps clarify why the shift makes sense for a lot of people once they’re stable.
Who Qualifies for Sublocade in Maryland
The clinical entry requirement is specific: you must be on a stable dose of transmucosal buprenorphine, meaning sublingual films or tablets, for a minimum of seven days before your first injection. This requirement exists because Sublocade is not a starting medication for someone in active withdrawal. You need to reach an established baseline on oral buprenorphine first.
Sublocade is approved for adults with moderate-to-severe opioid use disorder. Co-occurring mental health conditions, including depression, anxiety, and PTSD, do not disqualify you. Treatment for those conditions runs concurrently with Sublocade, and integrated care actually produces better outcomes than treating either condition in isolation.
If you’re dependent on fentanyl specifically, Sublocade is still an appropriate treatment path. Fentanyl-involved overdose deaths account for the overwhelming majority of Maryland’s opioid fatalities, and the clinical evidence supporting buprenorphine-based treatment applies to fentanyl dependence directly. The seven-day stabilization window on oral buprenorphine may feel like a delay when you’re ready to start, but it is the evidence-based on-ramp the medication requires.
Insurance and Medicaid Coverage in Maryland
Maryland Medicaid covers Sublocade. Prior authorization is required, but the steps are the provider’s responsibility to navigate, not yours. Your job before the first appointment is to confirm your coverage tier and have your insurance information ready. The provider’s office handles the prior authorization submission, the documentation of clinical necessity, and any appeals if the initial request is denied.
If you’re on a commercial plan, coverage varies by insurer, but most major carriers in Maryland cover Sublocade under their pharmacy or medical benefit. If you have no insurance, Maryland’s Behavioral Health Administration has expanded access pathways for uninsured patients seeking medication-assisted treatment, and the practice can walk you through those options at intake.
The concrete action: call the clinic before your first appointment and ask one direct question: “Does my insurance cover Sublocade, and what does the prior authorization process look like?” That call takes ten minutes and removes the biggest source of uncertainty before you walk in.
What Happens at Your First Sublocade Appointment
The first appointment follows a clear sequence. You start with an intake assessment, which covers your opioid use history, current medications, co-occurring conditions, and the documentation confirming your minimum seven days on transmucosal buprenorphine. A urine drug screen follows, along with prescription verification.
The injection itself is administered in the abdomen, subcutaneously, meaning just beneath the skin rather than into muscle. A licensed provider performs the injection in office. The full appointment, including intake and the injection, typically runs between 45 and 90 minutes for the first visit. Subsequent monthly visits are shorter since the intake assessment is already on file.
One requirement worth knowing: Sublocade is distributed exclusively through a Risk Evaluation and Mitigation Strategy program, referred to as the REMS program. Providers must be certified to prescribe and administer it, and Sublocade cannot be dispensed directly to patients to take home. This rule exists because the injectable formulation is not designed for self-administration and the depot mechanism requires proper subcutaneous placement to work correctly. Every practice administering Sublocade in Maryland is operating within that certified framework.
What the Injection Feels Like
Expect mild stinging at the injection site. After the injection, a small, firm lump forms under the skin. That lump is the depot, and it dissolves gradually over the month as buprenorphine is released. Most patients notice it for the first few days and then stop thinking about it.
Indivior’s Phase 3 trial reported injection-site conditions in approximately 30% of patients, and nearly all of those reactions were classified as mild to moderate. Common experiences include localized tenderness, slight swelling, or itching at the site in the first 48 hours. What is normal: any combination of those reactions that fades within a few days. What warrants a call to the clinic: significant pain that worsens after 72 hours, signs of infection such as redness spreading beyond the injection site, warmth, or discharge, or a lump that grows rather than shrinks over the first two weeks.
The First Week After Your Injection
Buprenorphine levels build over the first several days after the injection. Cravings do not typically disappear on day one, and expecting them to is one of the most common sources of discouragement early in treatment. The therapeutic level peaks within the first week and then holds relatively steady for the remainder of the month.
At the injection site, avoid aggressive pressure, rubbing, or any activity that puts direct force on the area for the first few days. Beyond that, there are no major activity restrictions. The one concrete action for this first week: keep a simple daily log of craving intensity, sleep quality, and any side effects. Bring that log to your next appointment. It gives your provider specific data to work with and gives you a way to track changes that would otherwise blur together in memory.
How Monthly Dosing Changes Your Recovery
The Haight et al. 2019 trial result bears repeating in practical terms: nearly 60% of Sublocade patients had no confirmed illicit opioid use over a five-month observation window, versus 16% in the placebo group. What that gap represents in daily life is the removal of a decision point. Daily oral buprenorphine works, but every morning you take it, the act of dosing reminds you that you’re managing a dependency. Once a month, the decision is made once. The rest of the month is just your life.
For family members reading this alongside a loved one: the first 30 days are about stabilization, not transformation. The second month tends to show clearer improvements in mood, sleep, and daily function as steady drug levels do their work. By 90 days, patients in treatment typically show measurable reductions in opioid craving, improved engagement in work or family life, and better tolerance for stress without defaulting to drug-seeking behavior. Those changes are realistic targets, not guarantees, but they are what the clinical data actually shows.
Understanding the broader mechanics of extended-release buprenorphine helps set expectations for how the depot system maintains therapeutic levels across the full 30-day cycle.
Staying on Track Between Injections
Sublocade addresses the pharmacological side of opioid use disorder. The behavioral side requires its own structure: regular counseling, check-in calls, and co-treatment for any mental health conditions running alongside the addiction. Maryland’s statewide telehealth expansion for behavioral health services, which accelerated significantly after 2020 according to Maryland Department of Health reporting, means you can access counseling remotely if in-person scheduling is a barrier.
The single most predictive factor for sustained recovery is continuity of treatment. Schedule your next injection before you leave the first appointment. Not next week, not when you feel ready. Before you walk out the door. That one step, taken while you’re already in the office, removes the friction that causes gaps in care.
Sublocade and Co-Occurring Mental Health Conditions
SAMHSA’s 2022 National Survey on Drug Use and Health found that 52.5% of adults with opioid use disorder also had a co-occurring mental health disorder. If you have depression, anxiety, PTSD, or any other diagnosed condition, you are in the majority of this patient population, not an exception to it.
Sublocade does not interfere with most psychiatric medications. Integrated treatment, meaning medication-assisted treatment running concurrently with behavioral health care, produces better outcomes than either approach used alone. The evidence on this is consistent across the literature, and a well-structured treatment program should build that integration into the care plan from the start.
Disclose every medication you take at intake. Not because judgment is involved, but because your provider needs the full picture to prescribe safely and to identify any pharmacological interactions before they become a problem.
Common Concerns About Sublocade (Answered Directly)
“Am I just replacing one drug with another?”
No. Buprenorphine binds opioid receptors and reduces compulsive use without producing the intoxication that defines active addiction. The American Society of Addiction Medicine is explicit on this point: medication-assisted treatment with buprenorphine is not substitution in any clinically meaningful sense. The goal of Sublocade is functional stability: the ability to work, maintain relationships, manage stress, and make decisions without opioid use driving the agenda. The measure of success is not the absence of medication. It is the presence of a functioning life.
“What if I want to stop taking Sublocade?”
Discontinuation is a decision you make with your provider, not on your own. Abrupt cessation significantly increases relapse risk because it removes the pharmacological stabilization that has been holding cravings in check. Tapering, when appropriate, is managed gradually and with clinical support. If you’re curious about what stopping looks like, raise the question at any appointment. A good provider will engage with it directly, not deflect it.
“Can I get Sublocade near me in Maryland?”
Yes. Locations across Maryland serve patients throughout the state, including Baltimore, College Park, Linthicum Heights, Nottingham, and Owings Mills. Telehealth intake options are available for patients outside those areas. If you’re trying to figure out where to access care close to you, confirming the nearest location and verifying insurance takes one phone call.
Your First Call Is the Only Step You Need to Take Today
Contact a Maryland Sublocade provider this week. Not to commit to a treatment plan, not to make any final decisions, just to get a benefits verification and ask one question about eligibility. Maryland Medicaid covers Sublocade, the prior authorization is the provider’s job to manage, and the first call is exactly what it sounds like: a conversation.
If you’re still gathering information on how to find a qualified provider in your area, that’s a reasonable place to start before picking up the phone. But the information will still be there next week. The call is the action that actually moves things forward.